2.08
-0.1(-4.59%)
Currency In NaN
| Previous Close | 2.18 |
| Open | 2.19 |
| Day High | 2.23 |
| Day Low | 2.08 |
| 52-Week High | 17.31 |
| 52-Week Low | 1.78 |
| Volume | 103,041 |
| Average Volume | 313,121 |
| Market Cap | 50.68M |
| PE | -0.36 |
| EPS | -5.81 |
| Moving Average 50 Days | 3.39 |
| Moving Average 200 Days | 8.66 |
| Change | -0.1 |
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
GlobeNewswire Inc.
Apr 28, 2025 8:35 PM GMT
Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster presentation to feature scalabi
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
GlobeNewswire Inc.
Apr 08, 2025 8:05 PM GMT
Dr. Banerjee’s appointment culminates Artiva’s efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapySAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a cl
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Mar 31, 2025 8:05 PM GMT
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune di